Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A new consolidated Locations section lists recruitment sites by state, replacing prior separate state location entries. This clarifies where the study is enrolling and expands access for potential participants.
    Difference
    0.8%
    Check dated 2025-12-23T17:32:56.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    Added comprehensive study details including the Efgartigimod PH20 SC treatment plan (up to 51 months) and long-term safety/tolerability endpoints. Expanded site list to 69 locations worldwide and updated timelines, enrollment, and eligibility criteria.
    Difference
    4%
    Check dated 2025-12-09T01:08:58.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2 on the page. No substantive changes to study content, eligibility criteria, or locations were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T17:54:44.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Removed the site-wide notice about government funding and NIH operating status from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T17:46:09.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Minor visual/layout updates to the Study Details page; core content such as objectives, eligibility criteria, outcomes, and locations remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T12:32:13.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    - Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.
    Difference
    4%
    Check dated 2025-10-05T17:23:39.000Z thumbnail image

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.